TSE:IMV - IMV Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
C$5.06 -0.27 (-5.07 %)
(As of 05/19/2019 04:32 AM ET)
Previous CloseC$5.06
Today's RangeC$5.06 - C$5.42
52-Week RangeC$3.95 - C$9.49
Volume24,300 shs
Average Volume45,906 shs
Market CapitalizationC$256.02 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. The company develops DPX-Survivac, T cell activating immunotherapy that is in Phase II clinical trials for ovarian cancer and diffuse large B-cell lymphoma. It also develops DPX-RSV, a B cell epitope peptide vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7; and vaccine candidates for malaria and the Zika virus. The company has collaboration and license agreement with Merck & Co., Inc., Dana-Farber Cancer Institute, Incyte Corporation, and Leidos Inc, as well as with Zoetis. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Receive IMV News and Ratings via Email

Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-902-4921819

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$68,000.00
Cash FlowC$0.69 per share
Book ValueC$0.55 per share

Profitability

Miscellaneous

Employees51
Market CapC$256.02 million
Next Earnings Date8/14/2019 (Estimated)
OptionableNot Optionable

IMV (TSE:IMV) Frequently Asked Questions

What is IMV's stock symbol?

IMV trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IMV."

How were IMV's earnings last quarter?

Imv Inc (TSE:IMV) posted its quarterly earnings results on Thursday, May, 9th. The company reported ($0.13) EPS for the quarter, topping the Zacks' consensus estimate of ($0.15) by $0.02. The company earned $0.08 million during the quarter. View IMV's Earnings History.

When is IMV's next earnings date?

IMV is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for IMV.

What price target have analysts set for IMV?

4 Wall Street analysts have issued twelve-month price objectives for IMV's shares. Their predictions range from C$10.40 to C$10.50. On average, they anticipate IMV's stock price to reach C$10.45 in the next year. This suggests a possible upside of 106.5% from the stock's current price. View Analyst Price Targets for IMV.

What is the consensus analysts' recommendation for IMV?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IMV.

Has IMV been receiving favorable news coverage?

Media headlines about IMV stock have trended negative on Sunday, according to InfoTrie. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. IMV earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future.

Who are some of IMV's key competitors?

What other stocks do shareholders of IMV own?

Who are IMV's key executives?

IMV's management team includes the folowing people:
  • Mr. Frederic Ors, Pres, CEO & Director (Age 45)
  • Mr. Pierre Labbé C.A., C.P.A., CPA, CA, ICD, Chief Financial Officer (Age 54)
  • Dr. Gabriela Nicola Rosu M.D., Chief Medical Officer
  • Mr. Joseph Sullivan, Sr. VP of Bus. Devel.
  • Mr. Marc Jasmin CPA, CMA, Sr. Director of Investor Relations & Communications

How do I buy shares of IMV?

Shares of IMV and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is IMV's stock price today?

One share of IMV stock can currently be purchased for approximately C$5.06.

How big of a company is IMV?

IMV has a market capitalization of C$256.02 million and generates C$68,000.00 in revenue each year. IMV employs 51 workers across the globe.

What is IMV's official website?

The official website for IMV is http://www.imvaccine.com/.

How can I contact IMV?

IMV's mailing address is 1344 Summer Street, Suite 412, HALIFAX, NS B3H 0A8, Canada. The company can be reached via phone at +1-902-4921819.


MarketBeat Community Rating for IMV (TSE IMV)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  62 (Vote Outperform)
Underperform Votes:  44 (Vote Underperform)
Total Votes:  106
MarketBeat's community ratings are surveys of what our community members think about IMV and other stocks. Vote "Outperform" if you believe IMV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel